MNMinh Ha Nguyen

Minh Ha Nguyen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minh Ha Nguyen has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Chan Hyuk Kim

    Research Institute of Pharmaceutical Sciences, Seoul National University, Gwanak-gu, Seoul, Korea (the Republic of)

    2 shared publications
  • Bohwa Han

    Department of Materials Science and Engineering, Seoul National University, Seoul, Republic of Korea

    1 shared publication
  • Cho I Park

    Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Daejeon, Korea (the Republic of)

    1 shared publication
  • Duck Cho

    Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication
  • Haneul Kim

    Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea

    1 shared publication
  • Hantae Jo

    Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

    1 shared publication

Latest Publications

  • Open Access

    Chimeric switch scaffold protein augments CAR synapse formation and signaling networks

    by Cho I Park, Segi Kim, Hwanyong Shim, Minh Ha Nguyen, Won-Ki Cho, Chan Hyuk Kim

    Background: Chimeric antigen receptor (CAR) T-cell therapy has achieved clinical success in hematologic malignancies, but remains limited in solid tumors due to immune checkpoint-mediated suppression and intrinsic signaling constraints. Unlike T-cell receptors (TCRs), CARs fail to efficiently recruit the linker for activation of T cells (LAT) signalosome, resulting in suboptimal signal propagation and unstable immunological synapse organization. Methods: To address this limitation, we engineered a programmed cell death protein 1 (PD-1)–LAT (PLAT) chimeric switch scaffold that couples PD-1 engagement to LAT-dependent proximal signaling. We compared the signaling kinetics, synaptic architecture, and antitumor efficacy of PLAT-expressing HER2 CAR T cells against those expressing conventional PD-1-CD28 switch receptors or dominant-negative PD-1 using biochemical signaling assays, quantitative imaging analysis, chronic antigen stimulation models, and in vivo xenograft validation. Results: PLAT enhanced LAT phosphorylation and nucleated LAT-associated signaling complexes on programmed death-ligand 1 engagement. This reorganized the CAR immune synapse into a concentric, TCR-like architecture, restoring proximal signaling strength. This signaling reprogramming resulted in increased calcium flux and NFAT/NF-κB activation, driving enhanced cytotoxicity, sustained proliferation, and resistance to functional exhaustion under chronic antigen exposure. In direct comparisons, PLAT outperformed conventional PD-1–CD28 switch receptors in early functional responses and demonstrated superior functional durability and antitumor activity in vivo compared with dominant-negative PD-1 strategies. Conclusions: These findings establish PLAT as a scaffold-based strategy that directly addresses intrinsic CAR signaling deficiencies by converting immune checkpoint engagement into LAT-dependent proximal signaling restoration. This work provides a new framework for engineering CAR T cells with improved function and persistence in immunosuppressive tumor environments.


  • Open Access

    Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis

    by Seung Kwon Koh, Hyojin Kim, Bohwa Han, Hantae Jo, Junsang Doh, Jeehun Park, Minh Ha Nguyen, Hyun-Young Kim, Haneul Kim, Seung-Hwan Lee, et al.

    Anti-CD19 chimeric antigen receptor (CAR)–engineered T and natural killer (NK) cell therapies have revolutionized the treatment of B-cell malignancies, but challenges including CD19 antigen loss greatly hinder their full therapeutic potential. Here, we revealed that cotreatment with anti-CD19 monoclonal antibody enhances antitumor activity of anti-CD19 CAR-T and -NK cells. Even though the treated antibody interferes with CD19 antigen binding of CAR, it significantly induces rapid detachment of anti-CD19 CAR effector cells from target cells, facilitating improved serial killing. This reduced interaction between CAR effector cells and target cells also leads to the alleviation of CAR-mediated trogocytosis. Interestingly, cotreatment with anti-CD19 antibody reveals time-dependent effects on the antitumor activity of anti-CD19 CAR-T cells, characterized by a reduction in early T cell activation followed by sustained high activity during prolonged exposure to target cells. This temporal modulation ultimately results in enhanced antitumor potency in vivo. These findings underscore the improved therapeutic efficacy achieved by combining anti-CD19 antibody with anti-CD19 CAR-T or -NK cells against B-cell malignancies.